Characterization of amoxicillin- and clavulanic acid-specific T cells in patients with amoxicillin-clavulanate-induced liver injury

Hepatology

Volumn 62, Issue 3, 2015, Pages 887-899

  Kim, Seung Hyun ^a,b   Saide, Katy ^a   Farrell, John ^a   Faulkner, Lee ^a   Tailor, Arun ^a   Ogese, Monday ^a   Daly, Ann K ^c   Pirmohamed, Munir ^a   Park, Kevin B ^a   Naisbitt, Dean ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b Ajou University School of Medicine   (South Korea)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR9; CHEMOKINE RECEPTOR CXCR3; CLAVULANIC ACID; GAMMA INTERFERON; HAPTEN; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN; INTERLEUKIN 22;

ADULT; AGED; ALLELE; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CLONE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; FEMALE; HLA SYSTEM; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MALE; MEDIATOR RELEASE; MIDDLE AGED; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TOXIC HEPATITIS; CASE CONTROL STUDY; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; DRUG EFFECTS; EPIDEMIOLOGY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; MONONUCLEAR CELL; REFERENCE VALUE;

AGED; AMOXICILLIN; AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; CASE-CONTROL STUDIES; CELL PROLIFERATION; CELLS, CULTURED; CLAVULANIC ACID; CLONE CELLS; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; REFERENCE VALUES; SAMPLING STUDIES;

EID: 84939653356     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27912     Document Type: Article

References (34)

1. Fontana RJ, Hayashi PH, Gu J, Reddy KR, Barnhart H, Watkins PB, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology 2014;147:96-108.
2. Daly AK, Donaldson PT, Bhatnagar P, Shen Y, Pe'er I, Floratos A, et al. HLA-B 5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009;41:816-819.
3. Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J 2008;8:186-195.
4. Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet 2010;42:711-714.
5. Spraggs CF, Budde LR, Briley LP, Bing N, Cox CJ, King KS, et al. HLA-DQA1 02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol 2011;29:667-673.
6. Schaid DJ, Spraggs CF, McDonnell SK, Parham LR, Cox CJ, Ejlertsen B, et al. Prospective validation of HLA-DRB1 07:01 allele carriage as a predictive risk factor for lapatinib-induced liver injury. J Clin Oncol 2014;32:2296-2303.
7. Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011;141:228-247.
8. Stephens C, Lopez-Nevot MA, Ruiz-Cabello F, Ulzurrun E, Soriano G, Romero-Gomez M, et al. HLA alleles influence the clinical signature of amoxicillin-clavulanate hepatotoxicity. PLoS One 2013;8:e68111.
9. Maria VA, Victorino RM. Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury. Gut 1997;41:534-540.
10. Jenkins RE, Meng X, Elliott VL, Kitteringham NR, Pirmohamed M, Park BK. Characterisation of flucloxacillin and 5-hydroxymethyl flucloxacillin haptenated HSA in vitro and in vivo. Proteomics Clin Appl 2009;3:720-729.
11. Monshi MM, Faulkner L, Gibson A, Jenkins RE, Farrell J, Earnshaw CJ, et al. Human leukocyte antigen (HLA)-B 57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology 2013;57:727-739.
12. Wuillemin N, Adam J, Fontana S, Krahenbuhl S, Pichler WJ, Yerly D. HLA haplotype determines hapten or p-i T cell reactivity to flucloxacillin. J Immunol 2013;190:4956-4964.
13. Wuillemin N, Terracciano L, Beltraminelli H, Schlapbach C, Fontana S, Krahenbuhl S, et al. T cells infiltrate the liver and kill hepatocytes in HLA-B57:01-associated floxacillin-induced liver injury. Am J Pathol 2014;184:1677-1682.
14. de Abajo FJ, Montero D, Madurga M, Garcia Rodriguez LA. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol 2004;58:71-80.
15. Donaldson PT, Daly AK, Henderson J, Graham J, Pirmohamed M, Bernal W, et al. Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. J Hepatol 2010;53:1049-1053.
16. O'Donohue J, Oien KA, Donaldson P, Underhill J, Clare M, MacSween RN, Mills PR. Co-amoxiclav jaundice: clinical and histological features and HLA class II association. Gut 2000;47:717-720.
17. Lucena MI, Molokhia M, Shen Y, Urban TJ, Aithal GP, Andrade RJ, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011;141:338-347.
18. Danan G, Benichou C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323-1330.
19. Naisbitt DJ, Nattrass RG, Ogese MO. In vitro diagnosis of delayed-type drug hypersensitivity: mechanistic aspects and unmet needs. Immunol Allergy Clin North Am 2014;34:691-705
20. Wu Y, Sanderson JP, Farrell J, Drummond NS, Hanson A, Bowkett E, et al. Activation of T cells by carbamazepine and carbamazepine metabolites. J Allergy Clin Immunol 2006;118:233-241.
21. + T-cell clones from patients with carbamazepine hypersensitivity. J Allergy Clin Immunol 2007;119:973-981.
22. Mauri-Hellweg D, Zanni M, Frei E, Bettens F, Brander C, Mauri D, et al. Cross-reactivity of T cell lines and clones to beta-lactam antibiotics. J Immunol 1996;157:1071-1079.
23. Britschgi M, Steiner UC, Schmid S, Depta JP, Senti G, Bircher A, et al. T-cell involvement in drug-induced acute generalized exanthematous pustulosis. J Clin Invest 2001;107:1433-1441.
24. Bomarrito L, Zisa G, Delrosso G, Farinelli P, Galimberti M. A case of acute generalized exanthematous pustulosis due to amoxicillin-clavulanate with multiple positivity to beta-lactam patch testing. Eur Ann Allergy Clin Immunol 2013;45:178-180.
25. Pichler WJ. Delayed drug hypersensitivity reactions. Ann Intern Med 2003;139:683-693.
26. Pichler WJ, Yawalkar N, Britschgi M, Depta J, Strasser I, Schmid S, et al. Cellular and molecular pathophysiology of cutaneous drug reactions. Am J Clin Dermatol 2002;3:229-238.
27. + T-cells with the potential to promote hepatocyte cytotoxicity in a mouse model. Toxicol Sci. 2015 Apr 14. pii: kfv077. [Epub ahead of print]
28. Cavani A, Pennino D, Eyerich K. Th17 and Th22 in skin allergy. Chem Immunol Allergy 2012;96:39-44.
29. Li J, Zhu X, Liu F, Cai P, Sanders C, Lee WM, Uetrecht J. Cytokine and autoantibody patterns in acute liver failure. J Immunotoxicol 2010;7:157-164.
30. Metushi IG, Zhu X, Chen X, Gardam MA, Uetrecht J. Mild isoniazid-induced liver injury in humans is associated with an increase in Th17 cells and T cells producing IL-10. Chem Res Toxicol 2014;27:683-689.
31. Sabat R, Ouyang W, Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov 2014;13:21-38.
32. Yanaba K, Yoshizaki A, Muroi E, Hara T, Ogawa F, Shimizu K, Sato S. The proteasome inhibitor bortezomib inhibits T cell-dependent inflammatory responses. J Leukoc Biol 2010;88:117-122.
33. Yanaba K, Asano Y, Tada Y, Sugaya M, Kadono T, Sato S. Proteasome inhibitor bortezomib ameliorates intestinal injury in mice. PLoS One 2012;7:e34587.
34. Mudnakudu Nagaraju KK, Babina M, Worm M. Opposing effects on immune function and skin barrier regulation by the proteasome inhibitor bortezomib in an allergen-induced eczema model. Exp Dermatol 2013;22:742-747.